Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

NCT07808697 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07808697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07808697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
August 30, 2029
Enrollment
300 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2